

Electronic Supplementary Material

A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[¹¹C]Rolipram

Journal: Molecular Imaging and Biology

Akihiro Takano¹, Tolga Uz², Jesus Garcia-Segovia^{3a}, Max Tsai^{2b}, Gezim Lahu², Nahid Amini¹, Ryuji Nakao¹, Zhisheng Jia¹, Christer Halldin¹

1. Karolinska Institutet, Department of Clinical Neuroscience, Center for Psychiatric Research, Stockholm, SWEDEN

2. Takeda Development Center Americas, Inc., Deerfield, IL, 60015, USA

3. Takeda Development Center, London, UK

Corresponding author: Akihiro Takano, MD, PhD.


Email: akihiro.takano@ki.se

Karolinska Institutet, Department of Clinical Neuroscience, Center for Psychiatric Research, Stockholm, SWEDEN


Current addresses:

a Orchard Therapeutics, Birch Lane, London UK


b Eli Lilly and Company, Indianapolis USA



Supplementary Figure 1. The time course of the plasma concentration of **a** roflumilast and **b** N-oxide roflumilast. Roflumilast was administered intravenously 3 h before the radioligand injection. The plasma concentration of roflumilast and N-oxide roflumilast was rather constant during the PET measurements. The plasma concentration of N-oxide roflumilast was higher than that of roflumilast.



Supplementary Figure 2. The relationship between PDE4 occupancy and the plasma concentration of N-oxide roflumilast and the sum of roflumilast and N-Oxide roflumilast. **a, c** The relationship based on the target occupancy using V_T . **b, d** The relationship based on the target occupancy using V_T/f_p .



Supplementary Figure 3. The change of the free fraction (%) of (R)-[¹¹C]rolipram at the baseline condition and after pretreatment with roflumilast. Before: the baseline condition, After: the condition after pretreatment with roflumilast. There was no clear trend of the change of the free fraction after the pretreatment with roflumilast.